Through this collaboration, the two organisations will mutually-selected CVI research and development projects with the goal of commercializing them and resulting intellectual property.
CDRD Ventures (CVI), the commercialization vehicle of the Canada-based Centre for Drug Research and Development (CDRD), and US-listed drugs maker Pfizer have extended an investment fund supporting projects with therapeutic potential stemming from academic discovery. Through this collaboration, the two organisations will mutually-selected CVI research and development projects with the goal of commercializing them and…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
